DVAX Dynavax Technologies
- 10.845
- -0.185-1.68%
Dynavax Technologies News
Dynavax Down 5% on FDA Complete Response Letter for Heplisav-B for Hemodialysis
UPDATE 1-US FDA Declines to Approve Expanded Use of Dynavax's Hepatitis B Vaccine
Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA
By Denny Jacob Dynavax disclosed that the Food and Drug Administration has ruled its application for its hepatitis B vaccine treatment didn't provide sufficient data to support the full evaluation of
FDA Issued Complete Response Letter To Dynavax Saying SBLA For Four-Dose HEPLISAV-B Regimen Did Not Provide Sufficient Data To Support Full Evaluation Of Effectiveness Or Safety
FDA Issued Complete Response Letter To Dynavax Saying SBLA For Four-Dose HEPLISAV-B Regimen Did Not Provide Sufficient Data To Support Full Evaluation Of Effectiveness Or Safety
Dynavax Provides Regulatory Update on SBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application...
Dynavax Technologies (NASDAQ:DVAX) Shareholders Are Still up 78% Over 5 Years Despite Pulling Back 7.8% in the Past Week
It hasn't been the best quarter for Dynavax Technologies Corporation (NASDAQ:DVAX) shareholders, since the share price has fallen 13% in that time. But at least the stock is up over the last five y
Analysts Are Updating Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates After Its First-Quarter Results
Dynavax Technologies Corp (DVAX) Q1 2024 Earnings: Aligns With EPS Projections, Surpasses ...
Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2024 Earnings Call Transcript
Dynavax Technologies Down Over 7%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk
Dynavax Technologies Corporation ( DVAX ) is currently at $10.80, down $0.85 or 7.25% --Would be lowest close since May 9, 2023, when it closed at $10.79 --On pace for largest percent decrease since
HC Wainwright & Co. : The Dynavax Technologies (DVAX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $29.00.
HC Wainwright & Co. : The Dynavax Technologies (DVAX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $29.00.
HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target
HC Wainwright & Co. analyst Edward White reiterates Dynavax Technologies with a Buy and maintains $29 price target.
Dynavax Technologies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 152.17% HC Wainwright & Co. → $29 Reiterates Buy → Buy 02/01/2024 73.91% Goldman Sachs → $20 In
Dynavax Technologies (DVAX) Q1 2024 Earnings Call Transcript
Earnings Call Summary | Dynavax Technologies(DVAX.US) Q1 2024 Earnings Conference
The following is a summary of the Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript:Financial Performance:Dynavax reported Q1 revenue from their hepatitis B vaccine, HEPLISAV-B,
Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
Dynavax Drops 6% as Quarterly Results Miss on Both Lines
Dynavax Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Dynavax Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Dynavax Reaffirms Full Year 2024 Financial Guidance; Expects Cash & Equivalents To Be Higher Y/Y At December 31, 2024
HEPLISAV-B net product revenue between approximately $265 - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany HEPLISAV-B gross margin o
Dynavax Technologies | 10-Q: Quarterly report
Analysis
Price Target
No Data
